AstraZeneca

News

AZ makes another cell therapy play with $1.2bn Gracell buy

AstraZeneca has lined up a $1.2 billion takeover deal for Chinese biotech Gracell Biotechnologies, bolting a series of cell therapies for cancer and autoimmune diseases on

News

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

AstraZeneca and Ionis are planning a US launch next month for Wainua, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (AT

News

Eisai files biliary tract cancer drug tasurgratinib in Japan

Eisai has filed for approval in Japan for tasurgratinib, its small-molecule fibroblast growth factor (FGF) receptor inhibitor, as a treatment for biliary tract cancers wit

News

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icos

News

ASH: AZ’s danicopan shows long-term benefit in PNH

New data with AstraZeneca’s oral Factor D inhibitor danicopan have built the case for the drug as an add-on to complement C5 antibodies for the treatment of paroxysmal noc

News

Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH

Novartis’ targeted factor B inhibitor iptacopan has become the first oral monotherapy to be approved by the FDA for rare blood disorder paroxysmal nocturnal haemoglobinuri

AZ makes another cell therapy play with $1.2bn Gracell buy

FDA approves Ionis, AZ’s Wainua for ATTR polyneuropathy

Eisai files biliary tract cancer drug tasurgratinib in Japan

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

ASH: AZ’s danicopan shows long-term benefit in PNH

Novartis’ Fabhalta is first FDA-cleared oral therapy for PNH

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

AstraZeneca

Editor's Picks